Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients
S Wang, X Han, X Hu, X Wang, L Zhao, L Tang… - Clinica chimica acta, 2014 - Elsevier
Background The use of biomarkers for selecting non-small cell lung cancer (NSCLC)
patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
[HTML][HTML] Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor …
MA Vollebergh, I Kappers, HM Klomp… - Journal of Thoracic …, 2010 - Elsevier
Introduction The selection of patients with non-small cell lung cancer (NSCLC) for epidermal
growth factor receptor (EGFR) inhibitor (EGFR-tyrosine kinase inhibitors [TKIs]) therapy is …
growth factor receptor (EGFR) inhibitor (EGFR-tyrosine kinase inhibitors [TKIs]) therapy is …
[HTML][HTML] Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase …
C Lazzari, A Spreafico, A Bachi, H Roder… - Journal of Thoracic …, 2012 - Elsevier
Introduction Our previous study showed that pretreatment serum or plasma Matrix-Assisted
Laser Desorption/Ionization Time-of-Flight Mass Spectrometry may predict clinical outcome …
Laser Desorption/Ionization Time-of-Flight Mass Spectrometry may predict clinical outcome …
A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small …
Y Liu, B Liu, XY Li, JJ Li, HF Qin, CH Tang… - Journal of Experimental …, 2011 - Springer
Background Epidermal growth factor receptor (EGFR) mutation is strongly associated with
the therapeutic effect of tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung …
the therapeutic effect of tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung …
Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients …
Y Jia, X Li, C Zhao, T Jiang, S Zhao, L Zhang, X Liu… - Lung Cancer, 2018 - Elsevier
Background Although EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are the standard
treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC), responses …
treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC), responses …
Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
JB Pan, YH Hou, GJ Zhang - Clinical Laboratory, 2014 - europepmc.org
Background The mutation at epidermal growth factor receptor (EGFR) is a clinical predictor
of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer (NSCLC) …
of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer (NSCLC) …
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non–small-cell lung cancer
Purpose Mutations in the epidermal growth factor receptor (EGFR) kinase domain can
predict tumor response to tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer …
predict tumor response to tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer …
Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV …
L Yang, C Tang, B Xu, W Wang, J Li, X Li, H Qin… - PLoS …, 2015 - journals.plos.org
Objectives Epidermal growth factor receptor (EGFR) gene mutations in tumors predict tumor
response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer …
response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer …
Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR‑TKIs in advanced non‑small‑cell lung cancer
Y Wang, J Duan, H Chen, H Bai, T An… - Oncology …, 2017 - spandidos-publications.com
The detection of mutations in the epidermal growth factor receptor (EGFR) gene in tumor
tissues has been established as the gold standard for predicting the efficacy of treatment …
tissues has been established as the gold standard for predicting the efficacy of treatment …
Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
ST Kim, JS Sung, UH Jo, KH Park, SW Shin, YH Kim - Medical Oncology, 2013 - Springer
The status of epidermal growth factor receptor (EGFR) and Kirsten ras (KRAS) mutations has
been used widely in management of patients with non-small cell lung cancer (NSCLC) …
been used widely in management of patients with non-small cell lung cancer (NSCLC) …
相关搜索
- small cell lung cancer
- egfr tkis lung cancer
- growth factor lung cancer
- tissue and plasma lung cancer
- chinese patients lung cancer
- receptor mutations lung cancer
- comparison of arms lung cancer
- direct sequencing lung cancer
- treatment response lung cancer
- interleukin 6 lung cancer
- lung adenocarcinoma patients
- markers in patients mutations of egfr
- tumor response stage iiib
- non-small cell
- tumor response lung cancer
- growth factor receptor mutations